Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (Q1)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -40.60%2.71M | -79.09%11.26M | -87.35%4.56M | -47.15%53.85M | 65.84%36.08M | 102.80%101.89M | -18.46%21.76M | -37.96%50.24M | --26.69M | 15.76%7.88M |
| Operating income | -40.60%2.71M | -79.09%11.26M | -87.35%4.56M | -47.15%53.85M | 65.84%36.08M | 102.80%101.89M | -18.46%21.76M | -37.96%50.24M | 26.69M | 15.76%7.88M |
| Cost of sales | 36.84%-1.92M | 81.60%-7.26M | 88.30%-3.04M | 51.89%-39.45M | -38.99%-25.97M | -100.62%-82M | 15.70%-18.69M | 34.89%-40.87M | ---22.17M | -8.48%-5.15M |
| Operating expenses | 36.84%-1.92M | 81.60%-7.26M | 88.30%-3.04M | 51.89%-39.45M | -38.99%-25.97M | -100.62%-82M | 15.70%-18.69M | 34.89%-40.87M | -22.17M | -8.48%-5.15M |
| Gross profit | -48.10%791K | -72.20%4M | -84.93%1.52M | -27.61%14.4M | 229.17%10.11M | 112.31%19.89M | -32.04%3.07M | -48.53%9.37M | 4.52M | 32.46%2.74M |
| Selling expenses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -5,057.14%-1.08M |
| Administrative expenses | 10.02%-28.29M | 39.94%-70.51M | 45.75%-31.44M | -4.40%-117.4M | 1.59%-57.95M | 22.56%-112.45M | -39.51%-58.89M | ---145.22M | ---42.22M | -25.36%-19.22M |
| Research and development expenses | 25.48%-76.73M | 49.73%-192.06M | 50.48%-102.97M | -9.22%-382.05M | -22.09%-207.94M | -1.57%-349.78M | -2.05%-170.32M | -71.92%-344.37M | ---166.9M | -90.41%-46.99M |
| Impairment and provision | -128.07%-9.95M | -1,390.58%-21.99M | -1,533.33%-4.36M | ---1.48M | ---267K | ---- | ---- | ---1.64M | ---2.94M | ---3.04M |
| -Other impairment is provision | -128.07%-9.95M | -1,390.58%-21.99M | -1,533.33%-4.36M | ---1.48M | ---267K | ---- | ---- | ---1.64M | ---2.94M | ---3.04M |
| Special items of operating profit | -22.38%8.23M | -91.78%3.26M | -60.51%10.61M | -47.89%39.68M | -21.10%26.86M | 106.26%76.13M | 104.53%34.05M | -3,770.62%-1.22B | ---751.25M | -95.41%751K |
| Operating profit | 16.34%-105.94M | 37.95%-277.29M | 44.75%-126.63M | -22.02%-446.85M | -19.31%-229.19M | 78.43%-366.21M | 79.97%-192.09M | -453.05%-1.7B | -958.79M | -209.72%-66.84M |
| Financing cost | 44.90%-3.97M | 17.07%-13.28M | 16.51%-7.2M | 9.18%-16.02M | 9.71%-8.63M | -16.28%-17.64M | -44.36%-9.55M | 5.62%-15.17M | ---6.62M | 5.30%-3.06M |
| Share of profit from joint venture company | 136.36%4K | -27.91%31K | -121.57%-11K | 100.19%43K | 102.00%51K | -684.04%-23.15M | -2,615.96%-2.55M | ---2.95M | ---94K | ---176K |
| Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---29.45M | ---- |
| Earning before tax | 17.89%-109.91M | 37.22%-290.54M | 43.70%-133.85M | -13.72%-462.82M | -16.44%-237.76M | 76.28%-406.99M | 79.48%-204.19M | -431.14%-1.72B | -994.95M | -182.44%-70.07M |
| Tax | -2.40%122K | 0.00%250K | 10.62%125K | 1.63%250K | -6.61%113K | 134.29%246K | 120.00%121K | -4.55%105K | --55K | 0.00%27K |
| After-tax profit from continuing operations | 17.90%-109.79M | 37.24%-290.29M | 43.73%-133.72M | -13.72%-462.57M | -16.45%-237.65M | 76.29%-406.75M | 79.49%-204.07M | -431.29%-1.72B | -994.9M | -182.64%-70.04M |
| Earning after tax | 17.90%-109.79M | 37.24%-290.29M | 43.73%-133.72M | -13.72%-462.57M | -16.45%-237.65M | 76.29%-406.75M | 79.49%-204.07M | -431.29%-1.72B | -994.9M | -182.64%-70.04M |
| Profit attributable to shareholders | 17.90%-109.79M | 37.24%-290.29M | 43.73%-133.72M | -13.72%-462.57M | -16.45%-237.65M | 76.29%-406.75M | 79.49%-204.07M | -441.82%-1.72B | -994.9M | -206.14%-70.04M |
| Basic earnings per share | 18.18%-0.27 | 36.84%-0.72 | 43.10%-0.33 | -21.28%-1.14 | -23.40%-0.58 | 89.94%-0.94 | 95.39%-0.47 | -106.18%-9.34 | -10.2 | -100.00%-0.72 |
| Diluted earnings per share | 18.18%-0.27 | 36.84%-0.72 | 43.10%-0.33 | -21.28%-1.14 | -23.40%-0.58 | 89.94%-0.94 | 95.39%-0.47 | -106.18%-9.34 | -10.2 | -100.00%-0.72 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Deloitte Touche Tohmatsu CPA LLP | -- | Deloitte Touche Tohmatsu CPA LLP | -- | Deloitte Touche Tohmatsu CPA LLP | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.